PEDF Overexpression Ameliorates Cardiac Lipotoxicity in Diabetic Cardiomyopathy via Regulation of Energy Metabolism.

Area of Science:

• Cardiology
• Metabolic Disorders
• Molecular Biology

Background:

• Diabetic cardiomyopathy (DCM) involves early cardiac energy metabolism changes and lipotoxicity.
• Myocardial lipid accumulation increases reactive oxygen species (ROS) and apoptosis.
• The role of Pigment epithelium-derived factor (PEDF) in DCM's metabolic and apoptotic pathways is unclear.

Purpose of the Study:

• Investigate PEDF's role in modulating cardiac energy metabolism in DCM.
• Determine PEDF's effect on ROS generation and apoptosis in DCM.
• Evaluate PEDF as a potential therapeutic agent for DCM.

Main Methods:

• Overexpressed PEDF in db/db mice using adeno-associated virus 9 (AAV9)-PEDF.
• Assessed cardiac hypertrophy, fibrosis, function, and energy metabolism at 24 weeks.
• Utilized HG+PA-treated H9c2 cells to analyze energy metabolism, ROS, and apoptosis.

Main Results:

• PEDF overexpression reversed cardiac remodeling in db/db mice with DCM.
• PEDF modulated energy metabolism, reduced lipotoxicity, and altered key protein expression (ATGL, Glut4, PPARα, CPT1α, CD36).
• PEDF reduced ROS generation and apoptosis in both mouse models and cell cultures.

Conclusions:

• PEDF effectively prevents DCM-related cardiac hypertrophy, fibrosis, and diastolic dysfunction.
• PEDF acts by modulating cardiac energy metabolism and reducing lipotoxicity-induced ROS and apoptosis.
• PEDF demonstrates therapeutic potential for managing diabetic cardiomyopathy.